Biotech Values

[DewDiligence]

> DNDN – I tend to agree with your analysis of DNDN's actions and timing of same… My own guess, like yours, is that they'll get the approvable letter pending 9902b, but I think DNDN is still a reasonable buy at these levels if you have a medium term investment horizon…<

You could be right but this is debatable. My own expectation is that DNDN will trade down to net cash—or slightly below net cash—if they do not get approval on the first review cycle.